Top

Published in:

Open Access 01-12-2010 | Review

Renal protection in diabetes: lessons from ONTARGET^®

Authors: Eberhard Ritz, Roland E Schmieder, Carol A Pollock

Published in: Cardiovascular Diabetology | Issue 1/2010

Abstract

Hypertension is an important independent risk factor for renal disease. If hypertension and chronic renal disease co-exist, as is common in patients with diabetes mellitus, the risk of cardiovascular disease is heightened. The importance of rigorous blood pressure control is recognized in current guidelines, with a recommended target of office blood pressure of < 130/80 mmHg; although ambulatory blood pressure may be more appropriate in order to identify the 24-hour hypertensive burden. Even lower blood pressure may further reduce the progression of chronic kidney disease, but the incidence of cardiovascular events may increase. Albuminuria not only indicates renal damage, but is also a powerful predictor of cardiovascular morbidity and mortality at least in patients with high cardiovascular risk and potentially pre-existing vascular damage. Management of the multiple factors for renal and cardiovascular disease is mandatory in the diabetic patient. The renin-angiotensin system (RAS) plays a pivotal role in the progression of renal disease, as well as in hypertension and target-organ damage. The use of agents that target the RAS confer renoprotection in addition to antihypertensive activity. There is extensive evidence of the renoprotective effect of angiotensin II receptor blockers (ARBs), and specifically telmisartan. In addition to providing 24-hour blood pressure control, clinical studies in patients with diabetes show that telmisartan improves renal endothelial function, prevents progression from microalbuminuria to macroalbuminuria, slows the decline in glomerular filtration rate and reduces proteinuria in overt nephropathy. These effects cannot be solely attributed to blood pressure control. In contrast to other members of the ARB class, the renoprotective effect of telmisartan is not confined to the management of diabetic nephropathy; slowing the progression of albuminuria has been demonstrated in the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET^®), which included diabetic and non-diabetic patients at high risk of cardiovascular events.

Available only for authorised users

Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008, 358: 1547-59. 10.1056/NEJMoa0801317.CrossRefPubMed

Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000, 342: 145-53. 10.1056/NEJM200001203420301.CrossRefPubMed

Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND®) Investigators: Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008, 372: 1174-83. 10.1016/S0140-6736(08)61193-9.CrossRefPubMed

Mann JF, Schmieder RE, Dyal L, McQueen MJ, Schumacher H, Pogue J, Wang X, Probstfield JL, Avezum A, Cardona-Munoz E, Dagenais GR, Diaz R, Fodor G, Maillon JM, Rydén L, Yu CM, Teo KK, Yusuf S, TRANSCEND® (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators: Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med. 2009, 7: 1-10.CrossRef

Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S, The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET®) Investigators: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET^® study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008, 372: 547-53. 10.1016/S0140-6736(08)61236-2.CrossRefPubMed

Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, Modification of Diet in Renal Disease Study Group: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999, 130: 461-70.CrossRefPubMed

Stevens LA, Coresh J, Greene T, Levey AS: Assessing kidney function--measured and estimated glomerular filtration rate. N Engl J Med. 2006, 354: 2473-83. 10.1056/NEJMra054415.CrossRefPubMed

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009, 150: 604-12.PubMedCentralCrossRefPubMed

Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C: Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005, 352: 2049-60. 10.1056/NEJMoa043161.CrossRefPubMed

10.

de Jong PE, Gansevoort RT: Screening techniques for detecting chronic kidney disease. Curr Opin Nephrol Hypertens. 2005, 14: 567-72. 10.1097/01.mnh.0000183948.13739.ee.CrossRefPubMed

11.

American Diabetes Association: Nephropathy in diabetes. Diabetes Care. 2004, 27 (Suppl 1): S79-S83.

12.

Levey AS, Cattran D, Friedman A, Miller WG, Sedor J, Tuttle K, Kasiske B, Hostetter T: Proteinuria as a surrogate outcome in CKD: Report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2009, 54: 205-226. 10.1053/j.ajkd.2009.04.029.CrossRefPubMed

13.

Yokoyama H, Sone H, Oishi M, Kawai K, Fukumoto Y, Kobayashi M, Japan Diabetes Clinical Data Management Study Group: Prevalence of albuminuria and renal insufficiency in type 2 diabetes: the Japanese Diabetes Clinical Data Management study (JDDM15). Nephrol Dial Transplant. 2009, 24: 1212-19. 10.1093/ndt/gfn603.CrossRefPubMed

14.

Iseki K, Ikemiya Y, Iseki C, Takishita S: Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003, 63: 1468-74. 10.1046/j.1523-1755.2003.00868.x.CrossRefPubMed

15.

Tonelli M, Jose P, Curhan G, Sacks F, Braunwald E, Pfeffer M, Cholesterol and Recurrent Events (CARE) Trial Investigators: Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ. 2006, 332: 1426-10.1136/bmj.38814.566019.2F.PubMedCentralCrossRefPubMed

16.

Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, UKPDS GROUP: Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003, 63: 225-32. 10.1046/j.1523-1755.2003.00712.x.CrossRefPubMed

17.

Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004, 164: 659-63. 10.1001/archinte.164.6.659.CrossRefPubMed

18.

Tomson C, Udayaraj U, Gilg J, Ansell D: Comorbidities in UK patients at the start of renal replacement therapy. Nephrol Dial Transplant. 2007, 22 (Suppl 7): vii58-vii68. 10.1093/ndt/gfm330.PubMed

19.

Eknoyan G: Cardiovascular mortality and morbidity in dialysis patients. Miner Electrolyte Metab. 1999, 25: 100-104. 10.1159/000057429.CrossRefPubMed

20.

Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001, 134: 629-36.CrossRefPubMed

21.

Patel A, ADVANCE Collaborative Group: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007, 370: 829-40. 10.1016/S0140-6736(07)61303-8.CrossRefPubMed

22.

Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B: Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Kidney Int Suppl. 2004, Review: S56-S58. 10.1111/j.1523-1755.2004.09214.x.CrossRef

23.

Hemann BA, Bimson WF, Taylor AJ: The Framingham Risk Score: an appraisal of its benefits and limitations. Am Heart Hosp J. 2007, 5: 91-96. 10.1111/j.1541-9215.2007.06350.x.CrossRefPubMed

24.

Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, Taskinen MR, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001, 24: 683-89. 10.2337/diacare.24.4.683.CrossRefPubMed

25.

Murray CJ, Lauer JA, Hutubessy RC, Niessen L, Tomijima N, Rodgers A, Lawes CM, Evans DB: Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet. 2003, 361: 717-25. 10.1016/S0140-6736(03)12655-4.CrossRefPubMed

26.

National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002, 39 (2 Suppl 1): S1-S266.

27.

Tryggvason K, Pettersson E: Causes and consequences of proteinuria: the kidney filtration barrier and progressive renal failure. J Intern Med. 2003, 254: 216-24. 10.1046/j.1365-2796.2003.01207.x.CrossRefPubMed

28.

Couser WG, Nangaku M: Cellular and molecular biology of membranous nephropathy. J Nephrol. 2006, 19: 699-705.PubMed

29.

Ladeia AM, Ladeia-Frota C, Pinho L, Stefanelli E, Adan L: Endothelial dysfunction is correlated with microalbuminuria in children with short-duration type 1 diabetes. Diabetes Care. 2005, 28: 2048-50. 10.2337/diacare.28.8.2048.CrossRefPubMed

30.

Ito H, Komatsu Y, Mifune M, Antoku S, Ishida H, Takeuchi Y, Togane M: The estimated GFR, but not the stage of diabetic nephropathy graded by the urinary albumin excretion, is associated with the carotid intima-media thickness in patients with type 2 diabetes mellitus: a cross-sectional study. Cardiovasc Diabetol. 2010, 9: 18-10.1186/1475-2840-9-18.PubMedCentralCrossRefPubMed

31.

Johnston CI, Risvanis J, Naitoh M, Tikkanen I: Mechanism of progression of renal disease: current hemodynamic concepts. J Hypertens Suppl. 1998, 16: S3-S7. 10.1097/00004872-199816010-00002.CrossRefPubMed

32.

Fagerudd JA, Pettersson-Fernholm KJ, Gronhagen-Riska C, Groop PH: The impact of a family history of Type II (non-insulin-dependent) diabetes mellitus on the risk of diabetic nephropathy in patients with Type I (insulin-dependent) diabetes mellitus. Diabetologia. 1999, 42: 519-26. 10.1007/s001250051189.CrossRefPubMed

33.

Vupputuri S, Sandler DP: Lifestyle risk factors and chronic kidney disease. Ann Epidemiol. 2003, 13: 712-20. 10.1016/S1047-2797(03)00066-8.CrossRefPubMed

34.

Keijzer-Veen MG, Schrevel M, Finken MJ, Dekker FW, Nauta J, Hille ET, Frölich M, van der Heijden BJ, Dutch POPS-19 Collaborative Study Group: Microalbuminuria and lower glomerular filtration rate at young adult age in subjects born very premature and after intrauterine growth retardation. J Am Soc Nephrol. 2005, 16: 2762-68. 10.1681/ASN.2004090783.CrossRefPubMed

35.

Li S, Chen SC, Shlipak M, Bakris G, McCullough PA, Sowers J, Stevens L, Jurkovitz C, McFarlane S, Norris K, Vassalotti J, Klag MJ, Brown WW, Narva A, Calhoun D, Johnson B, Obialo C, Whaley-Connell A, Becker B, Collins AJ, Kidney Early Evaluation Program Investigators: Low birth weight is associated with chronic kidney disease only in men. Kidney Int. 2008, 73: 637-42. 10.1038/sj.ki.5002747.CrossRefPubMed

36.

Vikse BE, Irgens LM, Leivestad T, Hallan S, Iversen BM: Low birth weight increases risk for end-stage renal disease. J Am Soc Nephrol. 2008, 19: 151-57. 10.1681/ASN.2007020252.PubMedCentralCrossRefPubMed

37.

Reyes L, Manalich R: Long-term consequences of low birth weight. Kidney Int Suppl. 2005, S107-S111. 10.1111/j.1523-1755.2005.09718.x. Suppl

38.

Mitchell P, Liew G, Rochtchina E, Wang JJ, Robaei D, Cheung N, Wong TY: Evidence of arteriolar narrowing in low-birth-weight children. Circulation. 2008, 118: 518-24. 10.1161/CIRCULATIONAHA.107.747329.CrossRefPubMed

39.

Liew G, Wang JJ, Duncan BB, Klein R, Sharrett AR, Brancati F, Yeh HC, Mitchell P, Wong TY, Atherosclerosis Risk in Communities Study: Low birthweight is associated with narrower arterioles in adults. Hypertension. 2008, 51: 933-38. 10.1161/HYPERTENSIONAHA.107.101584.CrossRefPubMed

40.

Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med. 2000, 342: 905-12. 10.1056/NEJM200003303421301.CrossRefPubMed

41.

Hsu CY, McCulloch CE, Darbinian J, Go AS, Iribarren C: Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med. 2005, 165: 923-28. 10.1001/archinte.165.8.923.CrossRefPubMed

42.

Keen H, Chlouverakis C, Fuller J, Jarrett RJ: The consomitants of raised blood sugar: studies in newly-detected hyperglycaemics. II. Urinary albumin excretion, blood pressure and their relation to blood sugar levels. Guys Hosp Rep. 1969, 118: 247-54.PubMed

43.

Janssen U, Riley SG, Vassiliadou A, Floege J, Phillips AO: Hypertension superimposed on type II diabetes in Goto Kakizaki rats induces progressive nephropathy. Kidney Int. 2003, 63: 2162-70. 10.1046/j.1523-1755.2003.00007.x.CrossRefPubMed

44.

Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994, 330: 877-84. 10.1056/NEJM199403313301301.CrossRefPubMed

45.

Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, Levey AS: The effect of lower target blood pressure on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease Study. Ann Intern Med. 2005, 142: 342-51.CrossRefPubMed

46.

Schrier RW, Estacio RO, Esler A, Mehler P: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002, 61: 1086-97. 10.1046/j.1523-1755.2002.00213.x.CrossRefPubMed

47.

de Galan BE, Chalmers J, Perkovic V, Ninomiya T, Pillai A, Patel A, Cass A, MacMahon S, Neal B, Mogensen CE, Marre M, Harrap SB, Poulter NR, Cooper ME, Mancia G, ADVANCE Collaborative Group: Renoprotection with perindopril-indapamide below current recommended blood pressure targets in patients with type 2 diabetes mellitus: Results of the ADVANCE trial. J Hypertens. 2008, 26 (Suppl 1): S188-S189.

48.

Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G, Esmatjes E, Gilbert RE, Hunsicker LG, de Faria JB, Mangili R, Moore J, Reisin E, Ritz E, Schernthaner G, Spitalewitz S, Tindall H, Rodby RA, Lewis EJ: Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol. 2005, 16: 3027-37. 10.1681/ASN.2004110919.CrossRefPubMed

49.

Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001, 345: 851-60. 10.1056/NEJMoa011303.CrossRefPubMed

50.

The ACCORD Study Group: Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. N Engl J Med. 2010, 17: 1575-85.

51.

Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B, Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology: 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007, 25: 1105-87. 10.1097/HJH.0b013e3281fc975a.CrossRefPubMed

52.

Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R: Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension. 2006, 47: 846-53. 10.1161/01.HYP.0000215363.69793.bb.CrossRefPubMed

53.

Moran A, Palmas W, Pickering TG, Schwartz JE, Field L, Weinstock RS, Shea S: Office and ambulatory blood pressure are independently associated with albuminuria in older subjects with type 2 diabetes. Hypertension. 2006, 47: 955-61. 10.1161/01.HYP.0000216634.73504.7d.CrossRefPubMed

54.

Gallego PH, Gilbey AJ, Grant MT, Bulsara MK, Byme GC, Jones TW, Frazer FL: Early changes in 24-hour ambulatory blood pressure are associated with high normal albumin excretion rate in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2005, 18: 879-85.CrossRefPubMed

55.

Palmas W, Pickering T, Teresi J, Schwartz JE, Eguchi K, Field L, Weinstock RS, Shea S: Nocturnal blood pressure elevation predicts progression of albuminuria in elderly people with type 2 diabetes. J Clin Hypertens (Greenwich). 2008, 10: 12-20. 10.1111/j.1524-6175.2007.07170.x.CrossRef

56.

Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME: Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens. 2005, 23: 463-73. 10.1097/01.hjh.0000160198.05416.72.CrossRefPubMed

57.

Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001, 345: 861-69. 10.1056/NEJMoa011161.CrossRefPubMed

58.

Haller HE: Prevention of microalbuminuria and cardiovascular morbidity with olmesartan - the ROADMAP trial [abstract 7026]. Program and abstract of the 42nd Annual Meeting and Scientific Exposition of the American Society of Nephrology. 2009, San Diego

59.

Bilous R, Chaturvedi N, Sjølie AK, Fuller J, Klein R, Orchard T, Porta M, Parving HH: Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med. 2009, 151: 11-20.CrossRefPubMed

60.

Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, Drummond K, Donnelly S, Goodyer P, Gubler MC, Klein R: Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009, 361: 40-51. 10.1056/NEJMoa0808400.PubMedCentralCrossRefPubMed

61.

Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, de Zeeuw D, de Jong PE, van Veldhuisen DJ, van Gilst WH: Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004, 110: 2809-16. 10.1161/01.CIR.0000146378.65439.7A.CrossRefPubMed

62.

de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004, 65: 2309-20. 10.1111/j.1523-1755.2004.00653.x.CrossRefPubMed

63.

de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004, 110: 921-27. 10.1161/01.CIR.0000139860.33974.28.CrossRefPubMed

64.

Weber M: The telmisartan Programme of Research tO show Telmisartan End-organ proteCTION (PROTECTION) programme. J Hypertens. 2003, 21 (Suppl 6): S37-S46.CrossRef

65.

Schmieder RE, Delles C, Mimran A, Fauvel JP, Ruilope LM: Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care. 2007, 30: 1351-56. 10.2337/dc06-1551.CrossRefPubMed

66.

Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S, INNOVATION Study Group: Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care. 2007, 30: 1577-78. 10.2337/dc06-1998.CrossRefPubMed

67.

Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J, Diabetics Exposed to Telmisartan and Enalapril Study Group: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004, 351: 1952-61. 10.1056/NEJMoa042274.CrossRefPubMed

68.

Barnett AH: Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL^®) study. Acta Diabetol. 2005, 42 (Suppl 1): S42-S49. 10.1007/s00592-005-0180-4.CrossRefPubMed

69.

Parving HH, Lehnert H, Broechner-Mortensen J, Gomis R, Andersen S, Arner P, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001, 345: 870-78. 10.1056/NEJMoa011489.CrossRefPubMed

70.

Bakris G, Burgess E, Weir M, Davidai G, Koval S: Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int. 2008, 74: 364-69. 10.1038/ki.2008.204.CrossRefPubMed

71.

Galle J, Schwedhelm E, Pinnetti S, Boger RH, Wanner C: Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant. 2008, 23: 3174-83. 10.1093/ndt/gfn230.CrossRefPubMed

72.

Baracskay D, Jarjoura D, Cugino A, Blend D, Rutecki GW, Whittier FC: Geriatric renal function: estimating glomerular filtration in an ambulatory elderly population. Clin Nephrol. 1997, 47: 222-28.PubMed

73.

Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM, Valsartan in Acute Myocardial Infarction Trial Investigators: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003, 349: 1893-906. 10.1056/NEJMoa032292.CrossRefPubMed

74.

Fagerudd J, Forsblom C, Pettersson-Fernholm K, Groop PH: Implementation of guidelines for the prevention of diabetic nephropathy. Diabetes Care. 2004, 27: 803-804. 10.2337/diacare.27.3.803.CrossRefPubMed

75.

Minutolo R, Sasso FC, Chiodini P, Cianciaruso B, Carbonara O, Zamboli P, Tirino G, Pota A, Torella R, Conte G, De Nicola L: Management of cardiovascular risk factors in advanced type 2 diabetic nephropathy: a comparative analysis in nephrology, diabetology and primary care settings. J Hypertens. 2006, 24: 1655-61. 10.1097/01.hjh.0000239303.93872.31.CrossRefPubMed

Title: Renal protection in diabetes: lessons from ONTARGET®
Authors: Eberhard Ritz
Roland E Schmieder
Carol A Pollock
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: Cardiovascular Diabetology / Issue 1/2010
Electronic ISSN: 1475-2840
DOI: https://doi.org/10.1186/1475-2840-9-60

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Renal protection in diabetes: lessons from ONTARGET^®

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

Azelnidipine protects myocardium in hyperglycemia-induced cardiac damage

Chromosome 9p21.3 polymorphism in a Chinese Han population is associated with angiographic coronary plaque progression in non-diabetic but not in type 2 diabetic patients

Differential expression of protein kinase C isoforms in coronary arteries of diabetic mice lacking the G-protein Gα11

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study

Metabolic syndrome predicts vascular changes in whole body magnetic resonance imaging in patients with long standing diabetes mellitus

Impact of Body Mass Index on the relationship of epicardial adipose tissue to metabolic syndrome and coronary artery disease in an Asian population

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page